Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: A pilot open-label study

Arthritis Research and Therapy

Volumn 19, Issue 1, 2017, Pages

  Grayson, Peter C ^a   Yazici, Yusuf ^b   Merideth, Melissa ^a   Sen, H Nida ^a   Davis, Michael ^a   Novakovich, Elaine ^a   Joyal, Elizabeth ^a   Goldbach Mansky, Raphaela ^a   Sibley, Cailin H ^a,c  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Anakinra; Autoinflammatory disease; Beh et's disease; Clinical trial; Vasculitis

Indexed keywords

ANAKINRA; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENITAL ULCER; HUMAN; INJECTION SITE REACTION; MALE; MIDDLE AGED; MOUTH ULCER; MYCOSIS; PILOT STUDY; REMISSION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; COMPLICATION; GYNECOLOGIC DISEASE; MALE GENITAL SYSTEM DISEASE; ULCER;

ADULT; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; ORAL ULCER; PILOT PROJECTS; ULCER; YOUNG ADULT;

EID: 85017172384     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-017-1222-3     Document Type: Article

References (17)

1. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656-62.
2. Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet's disease. Autoimmun Rev. 2015;14(1):1-9.
3. Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet's disease: a case series. Dermatology. 2014;228(3):211-4.
4. Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281-6.
5. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol. 2015;34(7):1293-301.
6. Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563-6.
7. Sibley CH, Plass N, Snow J, Wiggs E, Brewer C, King K, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease (NOMID) treated with anakinra. Arthritis Rheum. 2012;64(7):2375-86.
8. Forbess C, Swearingen C, Yazici Y. Behçet's Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Behçet's Disease Current Activity Form (BDCAF). Arthritis Rheum. 2008;58 Suppl 9:854.
9. Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: a quality of life measure specific to Behcet's disease. J Rheumatol. 2004;31(5):931-7.
10. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology. 1999;38(8):728-33.
11. Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behcet's disease. J Rheumatol. 1990;17(10):1428-9.
12. Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behcet's disease. Does interleukin-1 beta play a major role in Behcet's synovitis? Rheumatol Int. 2006;26(7):608-13.
13. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet. 2010;42(8):698-702.
14. Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behcet's syndrome-a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510-8.
15. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322(5):281-5.
16. Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V, et al. Current Status, goals, and research agenda for outcome measures development in Behcet Syndrome: report from OMERACT 2014. J Rheumatol. 2015;42(12):2436-41.
17. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258-67.